New psoriasis pill shows early promise in small safety trial
NCT ID NCT05453942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new oral drug called SAR441566 in 38 adults with mild to moderate psoriasis. Participants took the drug or a placebo twice daily for 4 weeks. The main goal was to check safety and tolerability, while also looking at changes in skin lesion severity. Results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAR441566 (an oral drug taken twice a day)
- What this could lead to
- If it works, this could point toward a new daily pill to ease psoriasis symptoms.
- What could go wrong
- This is a very early Phase 1 trial with only 38 people, so it is mainly checking safety, not effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number :2760001
Berlin, 10117, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis